Worth reading
49Recurring
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
13600
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of stock acquisition rights for stock compensation-type stock options (Maxvalu Tokai Co.,Ltd. Series 32 Stock Acquisition Rights)
Who receives how much
Up to 13,600 common shares (136 stock acquisition rights, 100 shares per right)
4 directors of the Company, excluding outside directors; number of shares allotted: 非開示
The lower thin line represents the existing number of shares to which these shares will be added.
Fair value for accounting purposes as of the allotment date
Amount of funds to be raised
No cash payment is required. Estimated net proceeds: Not disclosed
Total Stock-Based Compensation
The issue price of the stock acquisition rights constitutes director compensation equivalent to their accounting fair value as of the allotment date. Amount: Not disclosed
Terms of the stock acquisition rights
Exercise price
¥1 per share. Subject to adjustment in the event of a stock split or share consolidation.
Exercise period
From 16 July 2027 through 15 July 2042
Number of Stock Acquisition Rights
Up to 136 stock acquisition rights in total. Number of unexercised rights outstanding: Not disclosed
Reason for acquisition without consideration
Expiry of the exercise period, lapse of 5 years after retirement, a serious violation of laws or internal regulations, conviction resulting in imprisonment or a more severe penalty, appointment to a competing company without authorization, the death of a successor to the rights, waiver of all rights, or a resolution by the Board of Directors to acquire all or part of the rights.
Conditions on transfer restrictions
Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.
Transfer restriction period
Transfer of the stock acquisition rights is prohibited. The rights may be exercised only during the exercise period and within 5 years after retirement.
Categories and Number of Persons Covered
4 directors of the Company, excluding outside directors; number of shares allotted: Not disclosed
Intended allottee's holding policy
The stock acquisition rights may not be transferred or pledged as collateral. The rights may be exercised from 16 July 2027 through 15 July 2042, and after retirement only within 5 years from the date of retirement.
Basis for determining the amount to be paid
The issue price of the stock acquisition rights will be their accounting fair value as of the allotment date. Discount rate/premium rate: Not disclosed
Procedures under the Corporate Code of Conduct
The disclosure states that the eligible directors were elected or re-elected at the Annual General Meeting of Shareholders held on 19 May 2026. Whether an opinion was obtained from an independent third party: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of stock acquisition rights for stock compensation-type stock options (Maxvalu Tokai Co.,Ltd. Series 32 Stock Acquisition Rights) |
| Number of shares to be issued or disposed of | Up to 13,600 common shares (136 stock acquisition rights, 100 shares per right) |
| Issue price and disposal price | Fair value for accounting purposes as of the allotment date |
| Amount of funds to be raised | No cash payment is required. Estimated net proceeds: Not disclosed |
| Intended allottee | 4 directors of the Company, excluding outside directors; number of shares allotted: Not disclosed |
| Intended allottee's holding policy | The stock acquisition rights may not be transferred or pledged as collateral. The rights may be exercised from 16 July 2027 through 15 July 2042, and after retirement only within 5 years from the date of retirement. |
| Basis for determining the amount to be paid | The issue price of the stock acquisition rights will be their accounting fair value as of the allotment date. Discount rate/premium rate: Not disclosed |
| Exercise price | ¥1 per share. Subject to adjustment in the event of a stock split or share consolidation. |
| Exercise period | From 16 July 2027 through 15 July 2042 |
| Number of Stock Acquisition Rights | Up to 136 stock acquisition rights in total. Number of unexercised rights outstanding: Not disclosed |
| Transfer restriction period | Transfer of the stock acquisition rights is prohibited. The rights may be exercised only during the exercise period and within 5 years after retirement. |
| Reason for acquisition without consideration | Expiry of the exercise period, lapse of 5 years after retirement, a serious violation of laws or internal regulations, conviction resulting in imprisonment or a more severe penalty, appointment to a competing company without authorization, the death of a successor to the rights, waiver of all rights, or a resolution by the Board of Directors to acquire all or part of the rights. |
| Categories and Number of Persons Covered | 4 directors of the Company, excluding outside directors; number of shares allotted: Not disclosed |
| Total Stock-Based Compensation | The issue price of the stock acquisition rights constitutes director compensation equivalent to their accounting fair value as of the allotment date. Amount: Not disclosed |
| Procedures under the Corporate Code of Conduct | The disclosure states that the eligible directors were elected or re-elected at the Annual General Meeting of Shareholders held on 19 May 2026. Whether an opinion was obtained from an independent third party: Not disclosed |
Items this document does not state (13)
Total issue valueEstimated issuance expensesSpecific use of fundsPayment dateDilution RateTotal number of issued sharesConditions for lifting transfer restrictionsUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the link between directors’ compensation and the Company’s performance and share value, and to enhance their motivation and morale to improve performance over the medium to long term and increase corporate value by having them share with shareholders not only the benefits of a rise in the share price but also the risk of a decline.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.